SPRO
Spero Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
SPRO Profile
Spero Therapeutics, Inc.
A multi-asset, clinical-stage biopharmaceutical company focused on novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases
Pharmaceutical
Invalid Date
11/02/2017
NASDAQ Stock Exchange
32
12-31
Common stock
675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139
--
Spero Therapeutics, Inc., formerly known as Spero Therapeutics, LLC, was incorporated in December 2013 under the laws of the State of Delaware. The company is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and marketing new therapies for the treatment of MDR bacterial infections. The company also has a platform technology called "Potential Platform", which the company believes will develop drugs that can expand the scope and potency of existing antibiotics, including previously inactive antibiotics, against Gram-negative bacteria. The company believes that if the new product is successfully developed and approved, it will have meaningful impact and important commercial applications for the treatment of patients with MDR infection in community and hospital settings.